Inclusion of patient-centered, non-microbiological endpoints and biomarkers in tuberculosis drug trials DOI Creative Commons
Andrew R. DiNardo, Wilber Sabiiti, Stephen H. Gillespie

и другие.

Frontiers in Antibiotics, Год журнала: 2025, Номер 4

Опубликована: Май 22, 2025

Tuberculosis drug trials are primarily designed to identify antibiotic regimens with the strongest potency kill Mycobacterium tuberculosis . However, microbiologic cure is not synonymous improved health and recovery. Beyond antimicrobial efficacy, parameters such as morbidity mortality related lung function, cardiovascular health, cancer should be prioritized. This narrative review emphasizes critical need emphasize clinical outcomes much, if more, than microbiological endpoints. We examine underlying pathophysiological mechanisms determinants of non-microbiological in tuberculosis, providing a synthesis current knowledge. While there growing evidence for some biomarkers risk stratify TB patients all-cause mortality, relapse, or damage, no was found on TB-associated disease. In addition monitoring outcomes, treatment cohorts capture patient-centered dimensions more broadly. Finally, we highlight key research gaps opportunities evaluate biomarkers, aiming improve patient enable stratified approaches management.

Язык: Английский

A Year in Review on Tuberculosis and Non-tuberculous Mycobacteria Disease: A 2025 Update for Clinicians and Scientists DOI Creative Commons

Christoph Lange,

Graham Bothamley, Gunar Günther

и другие.

Pathogens and Immunity, Год журнала: 2025, Номер 10(2), С. 1 - 45

Опубликована: Март 2, 2025

In the field of tuberculosis and non-tuberculous mycobacterial (NTM) disease we are looking back on an exciting year 2024 with more than 10,000 publications listed in PubMed. Our aim, to review scientific literature 2024, is challenged by enormous number publications. Therefore, if your article not included or favorite mycobacteriology covered, please forgive us. "Year Review" very much clinically oriented lesser emphasis basic science, microbiology, biotechnology. Members steering committee Tuberculosis Network European Trials group (TBnet; www.tbnet.eu) report 139 fields epidemiology, prevention, diagnosis, treatment NTM diseases published that found particularly important. We separately for children adults provide a brief overview newer technologies diagnostic pipeline. Furthermore, summarize priorities research, development, implementation, all which represent perspective our combined clinical experience. This Year Review provides concise summary relevant highlights 2024.

Язык: Английский

Процитировано

0
The role of neutrophil response in lung damage and post-tuberculosis lung disease: a translational narrative review DOI Creative Commons
Ana Paula Santos, Luciana Silva Rodrigues, Nils Rother

и другие.

Frontiers in Immunology, Год журнала: 2025, Номер 16

Опубликована: Март 7, 2025

It is estimated that more than 150 million individuals alive in 2020 had survived tuberculosis (TB). A portion of this large population continues to experience chronic respiratory abnormalities, with or without symptoms, due previous active pulmonary TB. This condition known as Post-TB Lung Disease (PTLD), involves a complex interaction between pathogen, host and environmental factors. These interactions are believed drive hyperinflammatory process the lungs during TB, resulting tissue damage, which may lead radiological sequelae, impaired function, clinical such cough, dyspnea, hemoptysis, infections. Such complications impose significant health, financial, social burdens, remain poorly understood inadequately addressed by health care systems. Given heterogeneity immune cells their products infiltrating airways lung parenchyma acute inflammation caused Mycobacterium infection, it evident TB immunopathology multifactorial. Among various components involved, neutrophils have recently emerged critical contributors deleterious response against leading severe damage. In translational narrative review, we aim summarize role primary - proteases (such elastase), matrix metalloproteinases extracellular traps (NETs) We highlight new concepts emerging evidence neutrophil involvement disease, translating these insights from "bench bedside" facilitate dialogue fundamental researchers practitioners. Additionally, present potential targets for future treatment strategies could mitigate even prevent PTLD.

Язык: Английский

Процитировано

0
Post-tuberculosis lung disease: towards prevention, diagnosis, and care DOI
Jamilah Meghji, Sara C. Auld,

Gregory P. Bisson

и другие.

The Lancet Respiratory Medicine, Год журнала: 2025, Номер unknown

Опубликована: Март 1, 2025

Язык: Английский

Процитировано

0
Inclusion of patient-centered, non-microbiological endpoints and biomarkers in tuberculosis drug trials DOI Creative Commons
Andrew R. DiNardo, Wilber Sabiiti, Stephen H. Gillespie

и другие.

Frontiers in Antibiotics, Год журнала: 2025, Номер 4

Опубликована: Май 22, 2025

Tuberculosis drug trials are primarily designed to identify antibiotic regimens with the strongest potency kill Mycobacterium tuberculosis . However, microbiologic cure is not synonymous improved health and recovery. Beyond antimicrobial efficacy, parameters such as morbidity mortality related lung function, cardiovascular health, cancer should be prioritized. This narrative review emphasizes critical need emphasize clinical outcomes much, if more, than microbiological endpoints. We examine underlying pathophysiological mechanisms determinants of non-microbiological in tuberculosis, providing a synthesis current knowledge. While there growing evidence for some biomarkers risk stratify TB patients all-cause mortality, relapse, or damage, no was found on TB-associated disease. In addition monitoring outcomes, treatment cohorts capture patient-centered dimensions more broadly. Finally, we highlight key research gaps opportunities evaluate biomarkers, aiming improve patient enable stratified approaches management.

Язык: Английский

Процитировано

0